Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enXtra is a proprietary, standardized extract of **Alpinia galanga** (often called Thai ginger), developed as a caffeine-free nootropic that supports mental energy, alertness, and focus[1][2][4][7]. Clinically studied in healthy adults, enXtra has demonstrated the ability to increase alertness, reaction speed, and accuracy while reducing error rates and fatigue for up to five hours post-dose[3][5]. Its main mechanisms of action include:\n- **Dopamine transporter inhibition**: Compounds in Alpinia galanga bind to dopamine transporter proteins, reducing dopamine reuptake and enhancing dopamine signaling, particularly in attention-related neural pathways[1][5].\n- **Catechol-O-methyltransferase (COMT) inhibition**: Phytochemicals in Alpinia galanga inhibit COMT, the enzyme that breaks down dopamine, further sustaining dopamine's effects[1].\n- **Acetylcholinesterase inhibition**: Alpinia galanga compounds decrease acetylcholinesterase activity, increasing acetylcholine levels and supporting learning, memory, and sustained attention[1][5].\nThe product is non-GMO, gluten-free, vegan, and certified kosher and halal[1][6][7]. enXtra has obtained self-affirmed GRAS status in the USA and is approved for sale in North America, Europe, and Asia[1][2][4][7]. It is produced using a gentle, solvent-free, water-based extraction designed to preserve the rhizome's bioactive profile[1][7]. enXtra has a strong safety profile, showing no significant adverse cardiovascular, sleep, or habituation effects during studies[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on enxtra.